Immutep Ltd Sponsored ADR

Immutep Ltd Sponsored ADR is a biotechnology ADR representing Immutep Limited, an Australia-based clinical-stage company focused on developing LAG-3-related immunotherapies for cancer and autoimmune diseases. The company’s current pipeline centers on eftilagimod alfa, a soluble LAG-3 candidate being evaluated in multiple clinical programs across oncology, alongside additional product candidates such as IMP761, leramilimab, and other immunotherapy assets. Immutep’s work is aimed at modulating immune activity through its LAG-3 platform, with applications in solid tumors and immune-mediated conditions. As a sponsored ADR, it provides international investors access to a company active in the global biotechnology sector and engaged in drug development, clinical research, and immunology-focused therapeutics.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Marc Voigt

Headquarters

Sydney, NSW, Australia

Website

www.immutep.com